NCT05047458 is a Phase 1 clinical trial of ALXN2050 in Healthy, sponsored by Alexion Pharmaceuticals, Inc..

Who is sponsoring NCT05047458?

NCT05047458 is sponsored by Alexion Pharmaceuticals, Inc..

What drugs are being tested in NCT05047458?

Interventions in NCT05047458: ALXN2050, Placebo.

Is NCT05047458 still recruiting?

NCT05047458 is currently completed. Last updated 17 September 2021.

Last reviewed 2021-09-17 · How we verify

NCT05047458

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study of Single-dose ALXN2050 in Healthy Adults

Completed Phase 1 Last updated 17 September 2021

What this trial tests

Phase 1 trial testing ALXN2050 in Healthy in 28 participants. Completed in 13 April 2018.

Timeline

28 November 2017

Primary endpoint
13 April 2018

13 April 2018

Quick facts

Lead sponsor	Alexion Pharmaceuticals, Inc.
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	basic science
Enrollment	28
Start date	28 November 2017
Primary completion	13 April 2018
Estimated completion	13 April 2018
Sites	1 location across New Zealand

Drugs / interventions tested

ALXN2050 — full drug profile →
Placebo

Conditions studied

Healthy — all drugs for Healthy →

Sponsor

Alexion Pharmaceuticals, Inc. — full company profile →

Who can join

Adults 25 to 55, any sex, with Healthy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This was a phase 1, first-in-human, single-center, randomized, double-blind (participants and investigator blind, sponsor open) placebo-controlled, single-ascending dose study of ACH-0145228 (ALXN2050) conducted in healthy adult participants.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Refractory IgA Nephropathy: A Challenge for Future Nephrologists.
Di Leo V, Annese F, Papadia F, Russo MS, et al · · 2024 · cited 3× · PMID 38399561 · DOI 10.3390/medicina60020274

Verify or expand the search:

Other trials of ALXN2050

Trials testing the same drug.

NCT05218096 — Study of ALXN2050 in Adult Participants With Generalized Myasthenia Gravis · Phase 2 · terminated
NCT05259085 — Study of ALXN2050 in Participants With Hepatic Impairment · Phase 1 · terminated
NCT05097989 — Study of ALXN2050 in Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN) · Phase 2 · terminated
NCT05202145 — Drug-Drug Interaction (DDI) Study of ALXN2050 in Healthy Adult Participants · Phase 1 · completed
NCT04952545 — Study of ALXN2050 in Healthy Adult Participants of Japanese Descent · Phase 1 · completed

Other recruiting trials for Healthy

Currently open trials in the same condition.

NCT06707207 — Predicting Future Errors During Skill Performance · recruiting
NCT07169630 — PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI) · Phase 1 · recruiting
NCT07499414 — The Effects of the Bile Acid Supplement, 7-keto Lithocholic Acid, on Human Gut Microbiota and Risk Factors for Disease. · NA · recruiting
NCT07496697 — Effects of Electroacupuncture at NP82 and SP15 on Bowel Motility in Healthy Subjects · NA · recruiting
NCT06431932 — Pilot Trial of Fisetin in Healthy Volunteers and Older Patients With Multimorbidity · Phase 1, PHASE2 · recruiting

Other Alexion Pharmaceuticals, Inc. trials

Trials by the same sponsor.

NCT06015750 — Mitigate Immune-Mediated Loss of Therapeutic Response to Asfotase Alfa (STRENSIQ®) for Hypophosphatasia · Phase 4 · withdrawn
NCT07352423 — Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of ALXN2230 in Healthy Participants · Phase 1 · recruiting
NCT07221838 — A Study to Investigate OCS Tapering in Adult Participants With Generalized Myasthenia Gravis Treated With Ravulizumab · Phase 4 · recruiting
NCT07413250 — Assess Long-Term Safety of Danicopan Add-on Therapy in Participants With Paroxysmal Nocturnal Hemoglobinuria: Analysis o · active not recruiting
NCT07308574 — Post-Marketing Clinical Study of Ravulizumab in Participants With Clinical aHUS · Phase 4 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05047458 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Alexion Pharmaceuticals, Inc.
Last refreshed: 17 September 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05047458.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing